组织学很重要：个体化治疗非小细胞肺癌。
Histology matters: individualizing treatment in non-small cell lung cancer.
出版信息
Oncologist. 2010;15(1):3-5. doi: 10.1634/theoncologist.2009-0306. Epub 2010 Jan 19.
Abstract
This editorial discusses the role of histology in non-small cell lung cancer treatment.
摘要
这篇社论讨论了组织学在非小细胞肺癌治疗中的作用。
相似文献
1
Histology matters: individualizing treatment in non-small cell lung cancer.组织学很重要：个体化治疗非小细胞肺癌。
Oncologist. 2010;15(1):3-5. doi: 10.1634/theoncologist.2009-0306. Epub 2010 Jan 19.
2
MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic non-small cell lung cancer: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial.MO06.03 贝伐单抗与厄洛替尼联合，或贝伐单抗、顺铂与培美曲塞用于转移性非小细胞肺癌患者：SAKK19/09（BIOPRO）试验中基于表皮生长因子受体（EGFR）突变的治疗分配及疾病进展时的重复活检
Clin Adv Hematol Oncol. 2014 Jan;12(1 Suppl 1):13.
3
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.Ⅱ期序贯化疗联合西妥昔单抗与序贯化疗后西妥昔单抗治疗晚期非小细胞肺癌的选择设计试验：西南肿瘤协作组 S0342 研究。
J Clin Oncol. 2010 Nov 1;28(31):4747-54. doi: 10.1200/JCO.2009.27.9356. Epub 2010 Oct 4.
4
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?非小细胞肺癌的个体化医学：KRAS 是否是选择表皮生长因子受体靶向治疗患者的有用标志物？
J Clin Oncol. 2010 Nov 1;28(31):4769-77. doi: 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4.
5
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.厄洛替尼联合培美曲塞治疗晚期非小细胞肺癌（NSCLC）患者：一项 I 期剂量探索研究。
Ann Oncol. 2010 Nov;21(11):2233-2239. doi: 10.1093/annonc/mdq246. Epub 2010 May 5.
6
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).亚洲临床精选晚期非小细胞肺癌患者中吉非替尼对比卡铂/紫杉醇一线治疗的 III 期、随机、开放标签、前瞻性研究的生物标志物分析和最终总生存结果（IPASS）。
J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.
7
Molecular selection trumps clinical selection.分子选择胜过临床选择。
J Clin Oncol. 2011 Jul 20;29(21):2843-4. doi: 10.1200/JCO.2011.35.9208. Epub 2011 Jun 13.
8
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.基于血清质谱检测癌症患者的肿瘤表皮生长因子受体通路依赖性。
Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):358-65. doi: 10.1158/1055-9965.EPI-09-0937. Epub 2010 Jan 19.
9
[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].[非小细胞肺癌诊断与治疗策略的变化]
Magy Onkol. 2010 Jun;54(2):137-43. doi: 10.1556/MOnkol.54.2010.2.8.
10
Medical treatment of non-small-cell lung cancer.非小细胞肺癌的医学治疗
Ann Oncol. 2005;16 Suppl 2:ii229-32. doi: 10.1093/annonc/mdi721.
引用本文的文献
1
Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration.美国食品和药物管理局新药批准中外推法的使用。
JAMA Netw Open. 2022 Apr 1;5(4):e227958. doi: 10.1001/jamanetworkopen.2022.7958.
2
Exceptional Survival Among Kentucky Stage IV Non-small Cell Lung Cancer Patients: Appalachian Versus Non-Appalachian Populations.肯塔基州 IV 期非小细胞肺癌患者的卓越生存：阿巴拉契亚地区与非阿巴拉契亚地区人群比较。
J Rural Health. 2022 Jan;38(1):14-27. doi: 10.1111/jrh.12537. Epub 2020 Nov 18.
3
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers might be associated with lung adenocarcinoma risk: a nationwide population-based nested case-control study.血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂可能与肺腺癌风险相关：一项基于全国人群的巢式病例对照研究。
Am J Transl Res. 2020 Oct 15;12(10):6615-6625. eCollection 2020.
4
Drug Resistance to EGFR Inhibitors in Lung Cancer.肺癌对表皮生长因子受体抑制剂的耐药性
Chemotherapy. 2016;61(5):223-35. doi: 10.1159/000443368. Epub 2016 Feb 25.
5
Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma.非小细胞肺癌中前体 mRNA 剪接调节剂 SRSF1、SRSF2、SRPK1 和 SRPK2 的异常表达。
PLoS One. 2012;7(10):e46539. doi: 10.1371/journal.pone.0046539. Epub 2012 Oct 10.
6
Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer.S100A4、ephrin-A1 和骨桥蛋白在非小细胞肺癌中的表达。
BMC Cancer. 2012 Aug 1;12:333. doi: 10.1186/1471-2407-12-333.
7
Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung.肿瘤来源的血管内皮生长因子及其受体的表达与早期肺鳞癌的预后相关。
J Clin Oncol. 2012 Apr 1;30(10):1129-36. doi: 10.1200/JCO.2011.37.4231. Epub 2012 Feb 21.
8
One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancer.一个等位基因的缺失是另一个等位基因的获得：非小细胞肺癌中 NKX2-8 的改变。
Clin Cancer Res. 2011 Feb 15;17(4):638-9. doi: 10.1158/1078-0432.CCR-10-3081. Epub 2010 Dec 16.
9
Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC).审批总结：培美曲塞维持治疗晚期/转移性非鳞状非小细胞肺癌（NSCLC）。
Oncologist. 2010;15(12):1352-8. doi: 10.1634/theoncologist.2010-0224. Epub 2010 Dec 10.
10
Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer.应用原位显色杂交技术检测非小细胞肺癌和结直肠癌肺转移细针吸取细胞块中 EGFR 基因拷贝数。
J Exp Clin Cancer Res. 2010 Sep 15;29(1):125. doi: 10.1186/1756-9966-29-125.
本文引用的文献
1
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.培美曲塞维持治疗联合最佳支持治疗与安慰剂联合最佳支持治疗用于非小细胞肺癌：一项随机、双盲、3期研究
Lancet. 2009 Oct 24;374(9699):1432-40. doi: 10.1016/S0140-6736(09)61497-5. Epub 2009 Sep 18.
2
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.吉非替尼或卡铂-紫杉醇用于治疗肺腺癌。
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
3
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.培美曲塞、卡铂联合贝伐单抗一线治疗非鳞状非小细胞肺癌，继以培美曲塞和贝伐单抗维持治疗的II期研究。
J Clin Oncol. 2009 Jul 10;27(20):3284-9. doi: 10.1200/JCO.2008.20.8181. Epub 2009 May 11.
4
A novel five-antibody immunohistochemical test for subclassification of lung carcinoma.一种用于肺癌亚分类的新型五抗体免疫组织化学检测方法。
Mod Pathol. 2009 Aug;22(8):1032-43. doi: 10.1038/modpathol.2009.60. Epub 2009 May 8.
5
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.西妥昔单抗联合化疗治疗晚期非小细胞肺癌患者（FLEX）：一项开放标签的随机III期试验。
Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9.
6
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.化疗联合支持治疗可提高晚期非小细胞肺癌患者的生存率：一项对16项随机对照试验个体患者数据的系统评价和荟萃分析。
J Clin Oncol. 2008 Oct 1;26(28):4617-25. doi: 10.1200/JCO.2008.17.7162. Epub 2008 Aug 4.
7
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.一项III期研究，比较顺铂加吉西他滨与顺铂加培美曲塞用于初治晚期非小细胞肺癌患者的化疗效果。
J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27.
8
Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.在具有细支气管肺泡特征的肺腺癌中，黏液分化与表皮生长因子受体（EGFR）突变缺失及KRAS突变存在相关。
J Mol Diagn. 2007 Jul;9(3):320-6. doi: 10.2353/jmoldx.2007.060182.
9
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.KRAS突变是非小细胞肺癌中对表皮生长因子受体酪氨酸激酶抑制剂治疗耐药的重要预测指标。
Clin Cancer Res. 2007 May 15;13(10):2890-6. doi: 10.1158/1078-0432.CCR-06-3043.
10
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.单独使用紫杉醇-卡铂或联合贝伐单抗治疗非小细胞肺癌。
N Engl J Med. 2006 Dec 14;355(24):2542-50. doi: 10.1056/NEJMoa061884.
Zotero 插件